The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Prior to this, Maria held multiple roles at Novartis including Head of Global Manufacturing Functions, and Global Head of Manufacturing, Science & Technology
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
The settlement and dismissal resolves all claims between the parties
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
Subscribe To Our Newsletter & Stay Updated
